These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8748861)

  • 1. Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.
    Hirashima Y; Endo S; Hayashi N; Karasawa K; Nojima S; Takaku A
    Acta Neurochir (Wien); 1995; 137(1-2):15-8. PubMed ID: 8748861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor (PAF) and the development of chronic subdural haematoma.
    Hirasima Y; Endo S; Kato R; Ohmori T; Nagahori T; Nishijima M; Karasawa K; Nojima S; Takaku A
    Acta Neurochir (Wien); 1994; 129(1-2):20-5. PubMed ID: 7998491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of plasma and hematoma lipids related to choline glycerophospholipid in patients with chronic subdural hematoma.
    Hirashima Y; Nagahori T; Nishijima M; Endo S; Takaku A; Nakagawa Y
    Neurol Med Chir (Tokyo); 1994 Mar; 34(3):131-5. PubMed ID: 7516041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor and cerebral vasospasm following subarachnoid hemorrhage.
    Hirashima Y; Endo S; Otsuji T; Karasawa K; Nojima S; Takaku A
    J Neurosurg; 1993 Apr; 78(4):592-7. PubMed ID: 8450333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; PAF).
    Karasawa K; Fujita K; Satoh N; Hongo T; Setaka M; Ohno M; Nojima S
    J Biochem; 1987 Sep; 102(3):451-3. PubMed ID: 3429442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence for a putative involvement of platelet-activating factor in systemic lupus erythematosus without active nephritis.
    Denizot Y; Liozon E; Guglielmi L; Ly K; Soria P; Loustaud V; Vidal E; Jauberteau MO
    Mediators Inflamm; 2003 Apr; 12(2):101-5. PubMed ID: 12775360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local hypercoagulative activity precedes hyperfibrinolytic activity in the subdural space during development of chronic subdural haematoma from subdural effusion.
    Suzuki M; Kudo A; Kitakami A; Doi M; Kubo N; Kuroda K; Ogawa A
    Acta Neurochir (Wien); 1998; 140(3):261-5; discussion 265-6. PubMed ID: 9638263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory cytokines locally elevated in chronic subdural haematoma.
    Suzuki M; Endo S; Inada K; Kudo A; Kitakami A; Kuroda K; Ogawa A
    Acta Neurochir (Wien); 1998; 140(1):51-5. PubMed ID: 9522908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG.
    Bartemes KR; McKinney S; Gleich GJ; Kita H
    J Immunol; 1999 Mar; 162(5):2982-9. PubMed ID: 10072549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor.
    Leong HS; Mahesh BM; Day JR; Smith JD; McCormack AD; Ghimire G; Podor TJ; Rose ML
    J Leukoc Biol; 2008 Feb; 83(2):263-71. PubMed ID: 17974709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against platelet-activating factor in patients with antiphospholipid antibodies.
    Barquinero J; Ordi-Ros J; Selva A; Perez-Peman P; Vilardell M; Khamashta M
    Lupus; 1994 Feb; 3(1):55-8. PubMed ID: 8025588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of platelet activating factor and platelet associated IgG in pregnancy-induced hypertension].
    Zhang S; Zhang Y; Liu B
    Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):296-8. PubMed ID: 9206185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to platelet-activating factor (PAF) inhibit PAF-induced platelet aggregation.
    Smal MA; Cooney SJ; Baldo BA
    J Lipid Mediat; 1991 Nov; 4(3):333-41. PubMed ID: 1764578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colloid osmotic and hydrostatic pressures in chronic subdural haematomas.
    Gjerris F; Sørensen SC
    Acta Neurochir (Wien); 1980; 54(1-2):53-60. PubMed ID: 7435296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-platelet activating factor antibody and its effects on platelet aggregation.
    Tatsumi N; Terano Y; Hashimoto K; Hiyoshi M; Matsuura S
    Osaka City Med J; 1993 Nov; 39(2):167-74. PubMed ID: 8183536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural antibodies against phosphorylcholine as potential protective factors in SLE.
    Su J; Hua X; Concha H; Svenungsson E; Cederholm A; Frostegård J
    Rheumatology (Oxford); 2008 Aug; 47(8):1144-50. PubMed ID: 18522961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet and plasma platelet-activating factor in sepsis and myocardial infarction.
    Graham RM; Strahan ME; Norman KW; Watkins DN; Sturm MJ; Taylor RR
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):167-82. PubMed ID: 8012763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures.
    Nogami K; Hirashima Y; Endo S; Takaku A
    Brain Res; 1997 Apr; 754(1-2):72-8. PubMed ID: 9134961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse.
    Iñarrea P; Alonso F; Sanchez-Crespo M
    Immunopharmacology; 1983 Jun; 6(1):7-14. PubMed ID: 6347969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delineation of the role of platelet-activating factor in the immunoglobulin G2 antibody response.
    Al-Darmaki S; Knightshead K; Ishihara Y; Best A; Schenkein HA; Tew JG; Barbour SE
    Clin Diagn Lab Immunol; 2004 Jul; 11(4):720-8. PubMed ID: 15242947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.